CLINICAL ROLE -
Non-oral PrEP Options Are Being Investigated to Improve Patient Adherence
Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
Integrase Strand Transfer Inhibitors Associated With Weight Gain in Patients With HIV
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.
2 Clarke Drive Cranbury, NJ 08512